Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Evaluation of timed dexamethasone eye drops to prevent proliferative retinopathy of prematurity : a study protocol for a randomized intervention, multi-centre, double-blinded trial (DROPROP)

Hellström, Ann LU ; Petrishka-Lozenska, Mariya ; Pivodic, Aldina ; Nilsson, Anders K. LU ; Sjöbom, Ulrika ; Pupp, Ingrid Hansen LU orcid ; Ley, David LU ; Gränse, Lotta LU orcid ; Öhnell, Hanna Maria LU orcid and Jakobsson, Gunnar , et al. (2025) In BMC Pediatrics 25(1).
Abstract

Background: As the survival rate of preterm infants continues to rise worldwide, more infants are at risk of developing sight-threatening retinopathy of prematurity (ROP). Destructive retinal laser treatment and intravitreal injections of anti-vascular endothelial growth factor (VEGF), factor, which have potential systemic side effects, are necessary to prevent blindness in severe cases of ROP. Off-label use in clinical settings suggests that dexamethasone eye drops, 1 mg/ml, may prevent the progression of ROP to severe disease (Type 1 ROP) requiring treatment. Our current study aims to assess the efficacy and safety of timely administered dexamethasone eye drops to reduce the need for laser or anti-VEGF ROP treatment in preterm... (More)

Background: As the survival rate of preterm infants continues to rise worldwide, more infants are at risk of developing sight-threatening retinopathy of prematurity (ROP). Destructive retinal laser treatment and intravitreal injections of anti-vascular endothelial growth factor (VEGF), factor, which have potential systemic side effects, are necessary to prevent blindness in severe cases of ROP. Off-label use in clinical settings suggests that dexamethasone eye drops, 1 mg/ml, may prevent the progression of ROP to severe disease (Type 1 ROP) requiring treatment. Our current study aims to assess the efficacy and safety of timely administered dexamethasone eye drops to reduce the need for laser or anti-VEGF ROP treatment in preterm infants. Methods: In a randomized prospective interventional, multi-centre, double-blinded trial, we plan to include 100 infants with severe ROP born before gestational age 30 weeks in Sweden. Infants will be randomized to intervention with dexamethasone eye drops (1 mg/ml) (n = 50) or placebo, saline (n = 50) until either ROP is resolved or severe ROP (Type 1 ROP) development occurs, fulfilling ROP treatment criteria. Eye drops will be administered one drop per day or every other day, depending on the severity of ROP, with a maximum duration of 12 weeks. The primary objective is to evaluate whether dexamethasone intervention reduces the proportion of infants developing Type 1 ROP compared to infants receiving a placebo. Adverse events and potential side effects will be recorded, such as high intraocular pressure and growth restriction. Levels of cortisol in saliva and glucose in urine will be measured repeatedly. Secondary outcomes will include the timing of ROP progression, the recurrence rate after ROP treatment and retinal morphology. An ophthalmological follow-up will be initiated at 2 and 5.5 years of age, evaluating visual acuity, refractive errors, strabismus, retinal morphology and ophthalmological complications. All outcomes in the study will be compared between the infants receiving dexamethasone intervention and those receiving placebo. Discussion: Timely administration of dexamethasone eye drops may prevent severe ROP from progressing to Type 1 ROP, which requires treatment. This study aims to assess the efficacy and safety of dexamethasone intervention to support its clinical use and national guidelines. Trial registration: EudraCT, 2020–004933-19, registered in January 2021 and CTIS, 2023–505318-97–00, registered in August 2023. Clinical trial number: Not applicable.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Dexamethasone, Eye drops, Preterm infants, Retinopathy of prematurity
in
BMC Pediatrics
volume
25
issue
1
article number
332
publisher
BioMed Central (BMC)
external identifiers
  • pmid:40295974
  • scopus:105004336232
ISSN
1471-2431
DOI
10.1186/s12887-025-05673-x
language
English
LU publication?
yes
id
25ae7a9f-7baa-45e8-a502-2e00c97bae34
date added to LUP
2025-07-14 09:35:49
date last changed
2025-07-14 09:36:32
@article{25ae7a9f-7baa-45e8-a502-2e00c97bae34,
  abstract     = {{<p>Background: As the survival rate of preterm infants continues to rise worldwide, more infants are at risk of developing sight-threatening retinopathy of prematurity (ROP). Destructive retinal laser treatment and intravitreal injections of anti-vascular endothelial growth factor (VEGF), factor, which have potential systemic side effects, are necessary to prevent blindness in severe cases of ROP. Off-label use in clinical settings suggests that dexamethasone eye drops, 1 mg/ml, may prevent the progression of ROP to severe disease (Type 1 ROP) requiring treatment. Our current study aims to assess the efficacy and safety of timely administered dexamethasone eye drops to reduce the need for laser or anti-VEGF ROP treatment in preterm infants. Methods: In a randomized prospective interventional, multi-centre, double-blinded trial, we plan to include 100 infants with severe ROP born before gestational age 30 weeks in Sweden. Infants will be randomized to intervention with dexamethasone eye drops (1 mg/ml) (n = 50) or placebo, saline (n = 50) until either ROP is resolved or severe ROP (Type 1 ROP) development occurs, fulfilling ROP treatment criteria. Eye drops will be administered one drop per day or every other day, depending on the severity of ROP, with a maximum duration of 12 weeks. The primary objective is to evaluate whether dexamethasone intervention reduces the proportion of infants developing Type 1 ROP compared to infants receiving a placebo. Adverse events and potential side effects will be recorded, such as high intraocular pressure and growth restriction. Levels of cortisol in saliva and glucose in urine will be measured repeatedly. Secondary outcomes will include the timing of ROP progression, the recurrence rate after ROP treatment and retinal morphology. An ophthalmological follow-up will be initiated at 2 and 5.5 years of age, evaluating visual acuity, refractive errors, strabismus, retinal morphology and ophthalmological complications. All outcomes in the study will be compared between the infants receiving dexamethasone intervention and those receiving placebo. Discussion: Timely administration of dexamethasone eye drops may prevent severe ROP from progressing to Type 1 ROP, which requires treatment. This study aims to assess the efficacy and safety of dexamethasone intervention to support its clinical use and national guidelines. Trial registration: EudraCT, 2020–004933-19, registered in January 2021 and CTIS, 2023–505318-97–00, registered in August 2023. Clinical trial number: Not applicable.</p>}},
  author       = {{Hellström, Ann and Petrishka-Lozenska, Mariya and Pivodic, Aldina and Nilsson, Anders K. and Sjöbom, Ulrika and Pupp, Ingrid Hansen and Ley, David and Gränse, Lotta and Öhnell, Hanna Maria and Jakobsson, Gunnar and Sävman, Karin and Smith, Lois E.H. and Lundgren, Pia}},
  issn         = {{1471-2431}},
  keywords     = {{Dexamethasone; Eye drops; Preterm infants; Retinopathy of prematurity}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{BioMed Central (BMC)}},
  series       = {{BMC Pediatrics}},
  title        = {{Evaluation of timed dexamethasone eye drops to prevent proliferative retinopathy of prematurity : a study protocol for a randomized intervention, multi-centre, double-blinded trial (DROPROP)}},
  url          = {{http://dx.doi.org/10.1186/s12887-025-05673-x}},
  doi          = {{10.1186/s12887-025-05673-x}},
  volume       = {{25}},
  year         = {{2025}},
}